LibGuides: Coronavirus (COVID-19) Resource Center: Vaccine

Below is a list of links related to vaccines, and updated regularly:

Below is a list of articles related to vaccines, and updated regularly:

Zuo F, et al. "Mucosal IgA against SARS-CoV-2 Omicron Infection." November 24, 2022 N Engl J Med 2022; 387:e55 https://doi.org/10.1056/NEJMc2213153.
Chalkias S, et al. "Neutralization of Omicron Subvariant BA.2.75 after Bivalent Vaccination." NEJM November 23, 2022 https://doi.org/10.1056/NEJMc2212772.
Rubin E, et al. "Audio Interview: The FDA and Covid-19 Vaccines." November 17, 2022 N Engl J Med 2022; 387:e60 https://doi.org/10.1056/NEJMe2214911.
Jia M, et al. "Association between influenza vaccination and SARS-CoV-2 infection and its outcomes: systematic review and meta-analysis." Chin Med J (Engl). 2022 Nov 16. https://doi.org/10.1097/CM9.0000000000002427.
Hoss S, et al. "Myocarditis after BNT162b2 Vaccination in Israeli Adolescents." November 10, 2022 N Engl J Med 2022; 387:1816-1817 https://doi.org/10.1056/NEJMc2207270.
Canetti M, et al. "Six-Month Follow-up after a Fourth BNT162b2 Vaccine Dose." NEJM November 9, 2022 https://doi.org/10.1056/NEJMc2211283.
Jacob N, et al. "Effectiveness of the BNT162b2 (Pfizer-BioNTech) Vaccine in Children and Adolescents: A Systematic Review and Meta-Analysis." Vaccines (Basel). 2022 Nov 7;10(11). https://doi.org/10.3390/vaccines10111880.
Cheng W, et al. "Humoral and Cellular Response of Transplant Recipients to a Third Dose of mRNA SARS-CoV-2 Vaccine: A Systematic Review and Meta-analysis." Transplantation. 2022 Nov 4. https://doi.org/10.1097/TP.0000000000004386.
Chemaitelly H, et al. "Covid-19 Vaccine Protection among Children and Adolescents in Qatar." NEJM November 2, 2022 https://doi.org/10.1056/NEJMoa2210058.
Qin SX, et al. "Risk of glomerular diseases, proteinuria and hematuria following mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines." Nephrol Dial Transplant. 2022 Oct 28:gfac292. https://doi.org/10.1093/ndt/gfac292.
Rubin E, et al. "Audio Interview: Assessing the Effect of Vaccination and Prior SARS-CoV-2 Infection." October 27, 2022 N Engl J Med 2022; 387:e50 https://doi.org/10.1056/NEJMe2214027.
Frölke SC, et al. "Alternative strategies to increase the immunogenicity of COVID-19 vaccines in kidney transplant recipients not responding to two or three doses of an mRNA vaccine (RECOVAC): a randomised clinical trial." Lancet Infect Dis. 2022 Oct 27:S1473-3099(22)00650-8. https://doi.org/10.1016/S1473-3099(22)00650-8.
Chin E, et al. "Protection against Omicron from Vaccination and Previous Infection in a Prison System." NEJM October 26, 2022 https://doi.org/10.1056/NEJMoa2207082.
Anderson E, et al. "Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age." NEJM October 19, 2022 https://doi.org/10.1056/NEJMoa2209367.
Saunders G, et al. "Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial." Lancet Infect Dis. 2022 Oct 19. https://doi.org/10.1016/S1473-3099(22)00644-2.
Thukral H, et al. "Efficacy of Bacillus Calmette-Guerin (BCG) Vaccination in Reducing the Incidence and Severity of COVID-19 in High-Risk Population (BRIC): a Phase III, Multi-centre, Quadruple-Blind Randomised Control Trial." Infect Dis Ther. 2022 Oct 15. https://doi.org/10.1007/s40121-022-00703-y.
Xiong X, et al. "Risk of thyroid dysfunction associated with mRNA and inactivated COVID-19 vaccines: a population-based study of 2.3 million vaccine recipients." BMC Med. 2022 Oct 14;20(1):339. https://doi.org/10.1186/s12916-022-02548-1. (Original study)
Starkey T, et al. "Antibody response to a third booster dose of SARS-CoV-2 vaccination in adults with haematological and solid cancer: a systematic review." Br J Cancer. 2022 Oct 12. https://doi.org/10.1038/s41416-022-01951-y.
Baxter DN, et al. "Safety and Efficacy of the NVX-CoV2373 COVID-19 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial." Clin Infect Dis. 2022 Oct 10. https://doi.org/10.1093/cid/ciac803.
Havervall S, et al. "Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron Infection." October 6, 2022 N Engl J Med 2022; 387:1333-1336 https://doi.org/10.1056/NEJMc2209651.
Faraone J, et al. "Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants." October 6, 2022 N Engl J Med 2022; 387:1329-1331 https://doi.org/10.1056/NEJMc2210546.

Collie S, et al. "Effectiveness and Durability of the BNT162b2 Vaccine against Omicron Sublineages in South Africa." October 6, 2022 N Engl J Med 2022; 387:1332-1333 https://doi.org/10.1056/NEJMc2210093.
Iwagami M, et al. "Peripartum Outcomes Associated With COVID-19 Vaccination During Pregnancy: A Systematic Review and Meta-analysis." JAMA Pediatr. 2022 Oct 3. https://doi.org/10.1001/jamapediatrics.2022.3456.
Lowthian E, et al. "Risk of thrombocytopenic, haemorrhagic and thromboembolic disorders following COVID-19 vaccination and positive test: a self-controlled case series analysis in Wales." Sci Rep. 2022 Sep 30;12(1):16406. https://doi.org/10.1038/s41598-022-20118-6.
Li Y, et al. "A Systematic Review and Meta-analysis of the Association Between SARS-CoV-2 Vaccination and Myocarditis or Pericarditis." Am J Prev Med. 2022 Sep 26. https://doi.org/10.1016/j.amepre.2022.09.002.
Musa S, et al. "Improving COVID-19 Vaccine Uptake among Black Populations: A Systematic Review of Strategies." Int J Environ Res Public Health. 2022 Sep 22;19(19). https://doi.org/10.3390/ijerph191911971.
Li Y, et al. "A Systematic Review and Meta-analysis of the Association Between SARS-CoV-2 Vaccination and Myocarditis or Pericarditis." Am J Prev Med. 2022 Sep 26. https://doi.org/10.1016/j.amepre.2022.09.002.
Zeng D, et al. "Effects of Vaccination and Previous Infection on Omicron Infections in Children." September 22, 2022 N Engl J Med 2022; 387:1141-1143 https://doi.org/10.1056/NEJMc2209371.
Rubin E, et al. "Audio Interview: Can Vaccines Prevent Transmission of Covid-19?" September 22, 2022 N Engl J Med 2022; 387:e30 https://doi.org/10.1056/NEJMe2212576.
Thurner L, et al. "IL-1RA Antibodies in Myocarditis after SARS-CoV-2 Vaccination." NEJM September 21, 2022 https://doi.org/10.1056/NEJMc2205667.

Chalkias S, et al. "A Bivalent Omicron-Containing Booster Vaccine against Covid-19." NEJM September 16, 2022 https://doi.org/10.1056/NEJMoa2208343.

Chalkias S, et al. "A Bivalent Omicron-Containing Booster Vaccine against Covid-19." NEJM September 16, 2022 https://doi.org/10.1056/NEJMoa2208343.
Falsey AR, et al. "Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months." J Clin Invest. 2022 Sep 15;132(18):e160565. https://doi.org/10.1172/JCI160565.
Shahpari R, et al. "Evaluating the efficacy and safety of SpikoGen(R), an Advax-CpG55.2-adjuvanted severe acute respiratory syndrome coronavirus 2 spike protein vaccine: a phase 3 randomized placebo-controlled trial." Clin Microbiol Infect. 2022 Sep 10. https://doi.org/10.1016/j.cmi.2022.09.001.
Kargar R, et al. "Impact of incentives on COVID-19 vaccination; A systematic review." Front Med (Lausanne). 2022 Sep 8;9:810323. https://doi.org/10.3389/fmed.2022.810323. eCollection 2022.
Corbic Ramljak I, et al. "Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial." Lancet Infect Dis. 2022 Sep 5. https://doi.org/10.1016/S1473-3099(22)00502-3.
Barouch D, et al. "Covid-19 Vaccines — Immunity, Variants, Boosters." NEJM August 31, 2022 https://doi.org/10.1056/NEJMra2206573.
Liu Q, et al. "Comparison of the Effectiveness and Safety of Heterologous Booster Doses with Homologous Booster Doses for SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis." Int J Environ Res Public Health. 2022 Aug 29;19(17). https://doi.org/10.3390/ijerph191710752.
Obaid YY, et al. "Efficacy and safety of COVID-19 vaccines: A network meta-analysis." J Evid Based Med. 2022 Aug 23. https://doi.org/10.1111/jebm.12492.
Pepperrell T, et al. "Efficacy of Approved Versus Unapproved Vaccines for Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Randomized Blinded Clinical Trials." Open Forum Infect Dis. 2022 Aug 22;9(9):ofac408. https://doi.org/10.1093/ofid/ofac408. eCollection 2022 Sep.
Regan AK, et al. "Risk of preterm birth, small for gestational age at birth, and stillbirth after covid-19 vaccination during pregnancy: population based retrospective cohort study." BMJ. 2022 Aug 17;378:e071416. https://doi.org/10.1136/bmj-2022-071416.
Feng J, et al. "Myocarditis or Pericarditis Following the COVID-19 Vaccination in Adolescents: A Systematic Review." Vaccines (Basel). 2022 Aug 15;10(8):1316. https://doi.org/10.3390/vaccines10081316.
Hostetter ER, et al. "Multiple BCG vaccinations for the prevention of COVID-19 and other infectious diseases in type 1 diabetes." Cell Rep Med. 2022 Aug 15:100728. https://doi.org/10.1016/j.xcrm.2022.100728.
Kohane I, et al. "Understanding Covid Vaccine Efficacy over Time — Bridging a Gap Between Public Health and Health Care." August 11, 2022 N Engl J Med 2022; 387:483-485 https://doi.org/10.1056/NEJMp2201084.
Rasmussen SA, et al. "Covid-19 vaccination in pregnancy." BMJ. 2022 Aug 10;378:e069741. doi: 10.1136/bmj-2021-069741. (Systematic review)
Morciano C, et al. "Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: A multi-database, self-controlled case series study." PLoS Med. 2022 Jul 28;19(7):e1004056. https://doi.org/10.1371/journal.pmed.1004056. eCollection 2022 Jul.
Regele F, et al. "Three-Month Follow-Up of Heterologous vs. Homologous Third SARS-CoV-2 Vaccination in Kidney Transplant Recipients: Secondary Analysis of a Randomized Controlled Trial." Front Med (Lausanne). 2022 Jul 22;9:936126. https://doi.org/10.3389/fmed.2022.936126. eCollection 2022.
Heng D, et al. "Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age." NEJM July 20, 2022 https://doi.org/10.1056/NEJMoa2203209.
Wei X, et al. "Effectiveness and Cost-Effectiveness of Inactivated Vaccine to Address COVID-19 Pandemic in China: Evidence From Randomized Control Trials and Real-World Studies." Front Public Health. 2022 Jul 19;10:917732. https://doi.org/10.3389/fpubh.2022.917732. eCollection 2022.
Phornkittikorn P, et al. "An additional dose of viral vector COVID-19 vaccine and mRNA COVID-19 vaccine in kidney transplant recipients: A randomized controlled trial (CVIM 4 study)." Am J Transplant. 2022 Jul 16. https://doi.org/10.1111/ajt.17151.
Jiang Q, et al. "The Vaccine Efficacy Against the SARS-CoV-2 Omicron: A Systemic Review and Meta-Analysis." Front Public Health. 2022 Jul 13;10:940956. https://doi.org/10.3389/fpubh.2022.940956. eCollection 2022.
Laursen MV, et al. "Safety of heterologous primary and booster schedules with ChAdOx1-S and BNT162b2 or mRNA-1273 vaccines: nationwide cohort study." BMJ. 2022 Jul 13;378:e070483. https://doi.org/10.1136/bmj-2022-070483.
Di Girolamo R, et al. "COVID-19 vaccine and pregnancy outcomes: A systematic review and meta-analysis." Int J Gynaecol Obstet. 2022 Jul 10. https://doi.org/10.1002/ijgo.14336.
Altarawneh H, et al. "Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections." July 7, 2022 N Engl J Med 2022; 387:21-34 https://doi.org/10.1056/NEJMoa2203965.
Rubin E, et al. "Audio Interview: Designing the Next Covid-19 Vaccine." July 7, 2022 N Engl J Med 2022; 387:e6 https://doi.org/10.1056/NEJMe2209134.
Gallego A, et al. "Payers and Public Health: A Novel Collaboration to Support Covid-19 Vaccination Uptake." NEJM 6 July 2022. Vol. 3 No. 8 | August 2022 https://doi.org/10.1056/CAT.22.0058.
Zhao X, et al. "Omicron SARS-CoV-2 Neutralization from Inactivated and ZF2001 Vaccines." NEJM July 6, 2022 https://doi.org/10.1056/NEJMc2206900.
Winegar AL, et al. "Effect of Text Message Reminders and Vaccine Reservations on Adherence to a Health System COVID-19 Vaccination Policy: A Randomized Clinical Trial." JAMA Netw Open. 2022 Jul 1;5(7):e2222116. https://doi.org/10.1001/jamanetworkopen.2022.22116.
Orynbayev M, et al. "Efficacy and safety of an inactivated whole-virion vaccine against COVID-19, QazCovid-in(R), in healthy adults: A multicentre, randomised, single-blind, placebo-controlled phase 3 clinical trial with a 6-month follow-up." EClinicalMedicine. 2022 Jun 25;50:101526. https://doi.org/10.1016/j.eclinm.2022.101526. eCollection 2022 Aug.
Miller J, et al. "Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5." NEJM June 22, 2022 https://doi.org/10.1056/NEJMc2206576.

Vesco K, et al. "Evaluation of Acute Adverse Events after Covid-19 Vaccination during Pregnancy." NEJM June 22, 2022 https://doi.org/10.1056/NEJMc2205276.
Gerlovin H, et al. "Comparative Safety of BNT162b2 and mRNA-1273 Vaccines in a Nationwide Cohort of US Veterans." JAMA Intern Med. 2022 Jun 13. https://doi.org/10.1001/jamainternmed.2022.2109.
Yang R, et al. "Safety and efficacy of COVID-19 vaccines in children and adolescents: A systematic review of randomized controlled trials." J Med Virol. 2022 Jun 15. https://doi.org/10.1002/jmv.27940.
Reddy S, et al. "Persistence of immunity and impact of third dose of inactivated COVID-19 vaccine against emerging variants." Sci Rep. 2022 Jul 14;12(1):12038. https://doi.org/10.1038/s41598-022-16097-3.
Marchevsky NG, et al. "Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial." Lancet. 2022 Jun 11;399(10342):2212-2225. https://doi.org/10.1016/S0140-6736(22)00770-X.
Jaru-Ampornpan P, et al. "A Randomized Clinical Trial of a Fractional Low Dose of BNT162b2 Booster in Adults Following AZD1222." Vaccines (Basel). 2022 Jun 8;10(6). https://doi.org/10.3390/vaccines10060914.
Chilet-Rosell E, et al." Evaluation of Diagnostic Strategies for IdPadilla F, et al. Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial." Lancet Respir Med. 2022 Jun 7. https://doi.org/10.1016/S2213-2600(22)00180-1.
Zisman D, et al. "Predictors of Immunogenic Response to the BNT162b2 mRNA COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases Treated with Rituximab." Vaccines (Basel). 2022 Jun 6;10(6). https://doi.org/10.3390/vaccines10060901.
Chen X, et al. "Six-month follow-up of a booster dose of CoronaVac in two single-centre phase 2 clinical trials." Nat Commun. 2022 Jun 3;13(1):3100. https://doi.org/10.1038/s41467-022-30864-w.
Shokri S, et al. "Immunologic response, Efficacy, and Safety of Vaccines against COVID-19 Infection in Healthy and immunosuppressed Children and Adolescents Aged 2 - 21 years old: A Systematic Review and Meta-analysis." J Clin Virol. 2022 Aug;153:105196. https://doi.org/10.1016/j.jcv.2022.105196. Epub 2022 Jun 3.
Shaw PA, et al. "Effect of Text Messaging and Behavioral Interventions on COVID-19 Vaccination Uptake: A Randomized Clinical Trial." JAMA Netw Open. 2022 Jun 1;5(6):e2216649. https://doi.org/10.1001/jamanetworkopen.2022.16649.
Rubin E, et al. "Audio Interview: Waning Immunity against Covid-19." May 26, 2022 N Engl J Med 2022; 386:e64 https://doi.org/10.1056/NEJMe2206981.
Accorsi E, et al. "Effectiveness of Homologous and Heterologous Covid-19 Boosters against Omicron." NEJM May 25, 2022 https://doi.org/10.1056/NEJMc2203165.
Goldberg Y, et al. "Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2." NEJM May 25, 2022 https://doi.org/10.1056/NEJMoa2118946.
Brown P, et al. "Omicron BA.1/1.1 SARS-CoV-2 Infection among Vaccinated Canadian Adults." NEJM May 18, 2022 https://doi.org/10.1056/NEJMc2202879.
Evans J, et al. "Neutralization of the SARS-CoV-2 Deltacron and BA.3 Variants." NEJM May 18, 2022 https://doi.org/10.1056/NEJMc2205019.
Anderson E, et al. "Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age." NEJM May 11, 2022 https://doi.org/10.1056/NEJMoa2203315.
Rubin E, et al. "Audio Interview: Do We Need New Covid-19 Vaccines?" May 5, 2022 N Engl J Med 2022; 386:e52 https://doi.org/10.1056/NEJMe2205974.
Ten Doesschate T, et al. "Efficacy of Bacillus Calmette-Guerin vaccination against respiratory tract infections in the elderly during the Covid-19 pandemic." Clin Infect Dis. 2022 Mar 5. https://doi.org/10.1093/cid/ciac182.
Gray G, et al. "Effectiveness of Ad26.COV2.S and BNT162b2 Vaccines against Omicron Variant in South Africa." NEJM May 4, 2022 https://doi.org/10.1056/NEJMc2202061.
Nohynek H, et al. "Does the World Still Need New Covid-19 Vaccines?" NEJM May 4, 2022 https://doi.org/10.1056/NEJMe2204695.
Hager K, et al. "Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine." NEJM May 4, 2022 https://doi.org/10.1056/NEJMoa2201300.
Dai L, et al. "Efficacy and Safety of the RBD-Dimer–Based Covid-19 Vaccine ZF2001 in Adults." NEJM May 4, 2022 https://doi.org/10.1056/NEJMoa2202261.
Syed AA, et al. "Safety, efficacy, and immunogenicity of COVID-19 vaccines; a systematic review." Immunol Med. 2022 May 1:1-13. https://doi.org/10.1080/25785826.2022.2068331.
Noori M, et al. "Recent developments in SARS-CoV-2 vaccines: A systematic review of the current studies." Rev Med Virol. 2022 May 1:e2359. https://doi.org/10.1002/rmv.2359.

Zhou Q, et al. "Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis." BMC Med. 2022 May 23;20(1):200. https://doi.org/10.1186/s12916-022-02397-y.
Pashaei Z, et al. "Safety and Adverse Events Related to COVID-19 mRNA Vaccines; a Systematic Review." Arch Acad Emerg Med. 2022 May 22;10(1):e41. https://doi.org/10.22037/aaem.v10i1.1597. eCollection 2022.
Mockeliunas L, et al. "Safety and efficacy of BCG re-vaccination in relation to COVID-19 morbidity in healthcare workers: A double-blind, randomised, controlled, phase 3 trial." EClinicalMedicine. 2022 Jun;48:101414. https://doi.org/10.1016/j.eclinm.2022.101414. Epub 2022 May 12.
Husby A, et al. "SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents." JAMA Cardiol. 2022 Apr 20. https://doi.org/10.1001/jamacardio.2022.0583.
Jones CB, et al. "A Systematic Review of Coronavirus Disease 2019 Vaccine Efficacy and Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Disease." Open Forum Infect Dis. 2022 Apr 18;9(6):ofac138. https://doi.org/10.1093/ofid/ofac138. eCollection 2022 Jun.
Shi Y, et al. "Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Adolescents, Children, and Infants: A Systematic Review and Meta-Analysis." Front Public Health. 2022 Apr 14;10:829176. https://doi.org/10.3389/fpubh.2022.829176. eCollection 2022.
Magen O, et al. "Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting." NEJM April 13, 2022 https://doi.org/10.1056/NEJMoa2201688.
Offit P, et al. "Covid-19 Boosters — Where from Here?" NEJM April 13, 2022 https://doi.org/10.1056/NEJMe2203329.
Casanegra AI, et al. "Risk of venous thromboembolism after COVID-19 vaccination." J Thromb Haemost. 2022 Apr 10. https://doi.org/10.1111/jth.15725.
Yoon S, et al. "Protection with a Third Dose of mRNA Vaccine against SARS-CoV-2 Variants in Frontline Workers." NEJM April 6, 2022 https://doi.org/10.1056/NEJMc2201821.
Rubin E, et al. "Audio Interview: Do We Need a Fourth Dose of Covid Vaccine?" April 7, 2022 N Engl J Med 2022; 386:e45 https://doi.org/10.1056/NEJMe2204616.
Ramaiah V, et al. "Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India." Lancet. 2022 Apr 2;399(10332):1313-1321. https://doi.org/10.1016/S0140-6736(22)00151-9. (Original study)
Wang YP, et al. "SARS-CoV-2 vaccination in patients with inflammatory bowel disease: A systemic review and meta-analysis." J Chin Med Assoc. 2022 Apr 1;85(4):421-430. https://doi.org/10.1097/JCMA.0000000000000682.
Cheung PP, et al. "Effectiveness of heterologous and homologous covid-19 vaccine regimens: living systematic review with network meta-analysis." BMJ. 2022 May 31;377:e069989. https://doi.org/10.1136/bmj-2022-069989.
Rubin E, et al. "Audio Interview: Effectiveness of Covid-19 Vaccination in Children." March 31, 2022 N Engl J Med 2022; 386:e39 https://doi.org/10.1056/NEJMe2204268.
Klein N, et al. "Added Benefit of Covid-19 Vaccination after Previous Infection." March 31, 2022 N Engl J Med 2022; 386:1278-1279 https://doi.org/10.1056/NEJMe2201380.
Bansal V, et al. "Effectiveness and safety of SARS-CoV-2 vaccine in Inflammatory Bowel Disease patients: A systematic review, meta-analysis and meta-regression." Aliment Pharmacol Ther. 2022 Mar 30. https://doi.org/10.1111/apt.16913.
Dahlqwist E, et al. "Association of SARS-CoV-2 Vaccination During Pregnancy With Pregnancy Outcomes." JAMA. 2022 Mar 24. https://doi.org/10.1001/jama.2022.3271.
Alton GD, et al. "Association of COVID-19 Vaccination in Pregnancy With Adverse Peripartum Outcomes." JAMA. 2022 Mar 24. https://doi.org/10.1001/jama.2022.4255.
Moreira E, et al. "Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine." NEJM March 23, 2022 https://doi.org/10.1056/NEJMoa2200674.

Rubin E, et al. "Audio Interview: Can We Make More Effective Covid-19 Vaccines?" March 17, 2022 N Engl J Med 2022; 386:e36 https://doi.org/10.1056/NEJMe2203667.
Roel E, et al. "Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis." BMJ. 2022 Mar 16;376:e068373. https://doi.org/10.1136/bmj-2021-068373.

Gonen T, et al. "Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron." NEJM March 16, 2022 https://doi.org/10.1056/NEJMc2202542.
Stone RH, et al. "COVID-19 vaccination among pregnant people in the United States: a systematic review." Am J Obstet Gynecol MFM. 2022 Mar 10;4(4):100616. https://doi.org/10.1016/j.ajogmf.2022.100616.
Rohban T, et al. "BNT162b2 Vaccine Booster and Covid-19 Mortality." March 10, 2022 N Engl J Med 2022; 386:1000-1001 https://doi.org/10.1056/NEJMc2120044.
Liu Q, et al. "Effectiveness and Safety of SARS-CoV-2 Vaccines among Children and Adolescents: A Systematic Review and Meta-Analysis." Vaccines (Basel). 2022 Mar 10;10(3). https://doi.org/10.3390/vaccines10030421.
Sablerolles R, et al. "Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming." March 10, 2022 N Engl J Med 2022; 386:951-963 https://doi.org/10.1056/NEJMoa2116747.
Rubin E, et al. "Audio Interview: Making Covid-19 Vaccines Available around the World." March 10, 2022 N Engl J Med 2022; 386:e31 https://doi.org/10.1056/NEJMe2203379.
Abu-Raddad L, et al. "Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar." NEJM March 9, 2022 https://doi.org/10.1056/NEJMoa2200797.
Bachmann M, et al. "The Future of SARS-CoV-2 Vaccination." March 3, 2022 N Engl J Med 2022; 386:899-900 https://doi.org/10.1056/NEJMc2119437.
Jones LF, et al. "The Effectiveness of Interventions for Increasing COVID-19 Vaccine Uptake: A Systematic Review." Vaccines (Basel). 2022 Mar 3;10(3). https://doi.org/10.3390/vaccines10030386.
Abela IA, et al. "Antibody response in immunocompromised patients after the administration of SARS-CoV-2 vaccine BNT162b2 or mRNA-1273: A randomised controlled trial." Clin Infect Dis. 2022 Mar 2. https://doi.org/10.1093/cid/ciac169.
Taytard J, et al. "More on BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age." NEJM March 2, 2022 https://doi.org/10.1056/NEJMc2201556.
Andrews N, et al. "Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant." NEJM March 2, 2022 https://doi.org/10.1056/NEJMoa2119451.
Hunter D, et al. "Addressing Vaccine Inequity — Covid-19 Vaccines as a Global Public Good." NEJM February 23, 2022 https://doi.org/10.1056/NEJMe2202547.
Alunno A, et al. "EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update." Ann Rheum Dis. 2022 Feb 23. https://doi.org/10.1136/annrheumdis-2021-222006.
Hamdy NA, et al. "Efficacy and Effectiveness of SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis." Vaccines (Basel). 2022 Feb 23;10(3). https://doi.org/10.3390/vaccines10030350.
Madhi S, et al. "Population Immunity and Covid-19 Severity with Omicron Variant in South Africa." NEJM February 23, 2022 https://doi.org/10.1056/NEJMoa2119658.
Abu-Raddad LJ, et al. "Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression." Lancet. 2022 Feb 21. https://doi.org/10.1016/S0140-6736(22)00152-0.

Ashurov A, et al. "Determining the reliability of rapid SARS-CoV-2 antigen detection in fully vaccinated individuals." J Clin Virol. 2022 Feb 19;148:105119. https://doi.org/10.1016/j.jcv.2022.105119.
Hall V, et al. "Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection." NEJM February 16, 2022 https://doi.org/10.1056/NEJMoa2118691.
Hammerman A, et al. "Effectiveness of the BNT162b2 Vaccine after Recovery from Covid-19." NEJM February 16, 2022 https://doi.org/10.1056/NEJMoa2119497.
Altarawneh H, et al. "Protection against the Omicron Variant from Previous SARS-CoV-2 Infection." NEJM February 9, 2022 https://doi.org/10.1056/NEJMc2200133.
Mayr F, et al. "Effectiveness of Homologous or Heterologous Covid-19 Boosters in Veterans." NEJM February 9, 2022 https://doi.org/10.1056/NEJMc2200415.
Sadoff J, et al. "Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S." NEJM February 9, 2022 https://doi.org/10.1056/NEJMoa2117608.
Collie S, et al. "Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa." February 3, 2022 N Engl J Med 2022; 386:494-496 https://doi.org/10.1056/NEJMc2119270.
Harville T, et al. "Anti-idiotype Antibodies in SARS-CoV-2 Infection and Vaccination." February 2, 2022 https://doi.org/10.1056/NEJMc2119443.
Wang Y, et al. "Herpes zoster related hospitalization after inactivated (CoronaVac) and mRNA (BNT162b2) SARS-CoV-2 vaccination: A self-controlled case series and nested case-control study." Lancet Reg Health West Pac. 2022 Apr;21:100393. https://doi.org/10.1016/j.lanwpc.2022.100393. Epub 2022 Feb 2.
Budi DS, et al. "mRNA Covid-19 vaccines in pregnancy: A systematic review." PLoS One. 2022 Feb 2;17(2):e0261350. https://doi.org/10.1371/journal.pone.0261350. eCollection 2022.
Bouzas MB, et al. "Immunogenicity induced by the use of alternative vaccine platforms to deal with vaccine shortages in a low- to middle-income country: Results of two randomized clinical trials." Lancet Reg Health Am. 2022 May;9:100196. https://doi.org/10.1016/j.lana.2022.100196. Epub 2022 Feb 2.
McConeghy K, et al. "Evaluating the Findings of the IMPACT-C Randomized Clinical Trial to Improve COVID-19 Vaccine Coverage in Skilled Nursing Facilities." JAMA Intern Med. 2022 Jan 31. https://doi.org/10.1001/jamainternmed.2021.8067.
Guo X, et al. "Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial." Nat Med. 2022 Feb;28(2):401-409. https://doi.org/10.1038/s41591-021-01677-z. Epub 2022 Jan 27.

Rubin E, et al. "Audio Interview: Addressing the Omicron Variant of SARS-CoV-2." January 27, 2022 N Engl J Med 2022; 386:e16 https://doi.org/10.1056/NEJMe2201214.
Andrews N, et al. "Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines." January 27, 2022 N Engl J Med 2022; 386:340-350 https://doi.org/10.1056/NEJMoa2115481.
Chemaitelly H, et al. "Waning mRNA-1273 Vaccine Effectiveness against SARS-CoV-2 Infection in Qatar." NEJM January 26, 2022 https://doi.org/10.1056/NEJMc2119432.
Pajon R, et al. "SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination." NEJM January 26, 2022 https://doi.org/10.1056/NEJMc2119912.
Atmar R, et al. "Homologous and Heterologous Covid-19 Booster Vaccinations." NEJM January 26, 2022 https://doi.org/10.1056/NEJMoa2116414.
Takashita E, et al. "Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant." NEJM January 26, 2022 https://doi.org/10.1056/NEJMc2119407.
Zhao X, et al. "Effects of a Prolonged Booster Interval on Neutralization of Omicron Variant." NEJM January 26, 2022 https://doi.org/10.1056/NEJMc2119426.
Veroniki AA, et al. "Vaccines to prevent COVID-19: A living systematic review with Trial Sequential Analysis and network meta-analysis of randomized clinical trials." PLoS One. 2022 Jan 21;17(1):e0260733. https://doi.org/10.1371/journal.pone.0260733. eCollection 2022.
Clemens R, et al. "Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study." Lancet. 2022 Jan 21. https://doi.org/10.1016/S0140-6736(22)00094-0.
Chemaitelly H, et al. "Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar." NEJM January 19, 2022 https://doi.org/10.1056/NEJMc2117933.
Tran TM, et al. "Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine." Biomed Pharmacother. 2022 Jan 19;147:112650. https://doi.org/10.1016/j.biopha.2022.112650.
Liu N, et al. "BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age." NEJM January 19, 2022 https://doi.org/10.1056/NEJMc2118775.
Sablerolles R, et al. "Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming." NEJM January 19, 2022 https://doi.org/10.1056/NEJMoa2116747.
Tobudic S, et al. "Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial." Ann Rheum Dis. 2022 Jan 13. https://doi.org/10.1136/annrheumdis-2021-221558.

Rössler A, et al. "SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons." NEJM January 12, 2022 https://doi.org/10.1056/NEJMc2119236.
Lin D, et al. "Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina." NEJM January 12, 2022 https://doi.org/10.1056/NEJMoa2117128.
Olson S, et al. "Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents." NEJM January 12, 2022 https://doi.org/10.1056/NEJMoa2117995.
Rastmanesh R, et al. "Covid-19 Infections in Vaccinated Health Care Workers." NEJM January 5, 2022 https://doi.org/10.1056/NEJMc2117817.
Veiga-Gutierrez R, et al. "Effects of Loigolactobacillus coryniformis K8 CECT 5711 on the Immune Response of Elderly Subjects to COVID-19 Vaccination: A Randomized Controlled Trial." Nutrients. 2022 Jan 5;14(1). https://doi.org/10.3390/nu14010228.
Eyre D, et al. "Effect of Covid-19 Vaccination on Transmission of Alpha and Delta Variants." NEJM January 5, 2022 https://doi.org/10.1056/NEJMoa2116597.
Schmidt F, et al. "Plasma Neutralization of the SARS-CoV-2 Omicron Variant." NEJM December 30, 2021 https://doi.org/10.1056/NEJMc2119641.
Collie S, et al. "Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa." NEJM December 29, 2021 https://doi.org/10.1056/NEJMc2119270.
MacKinnon-Cameron D, et al. "Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial." Lancet. 2022 Jan 15;399(10321):237-248. https://doi.org/10.1016/S0140-6736(21)02753-7. Epub 2021 Dec 23.
Lacy J, et al. "VITT and Second Doses of Covid-19 Vaccine." NEJM December 22, 2021 https://doi.org/10.1056/NEJMc2118507.
Fosbol E, et al. "SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study." BMJ. 2021 Dec 16;375:e068665. https://doi.org/10.1136/bmj-2021-068665.
Foxworth R, et al. "Covid-19 Vaccination in American Indians and Alaska Natives — Lessons from Effective Community Responses." NEJM December 18, 2021 https://doi.org/10.1056/NEJMp2113296.
Rubin E, et al. "Audio Interview: How Much Protection Does Prior SARS-CoV-2 Infection Provide?" December 16, 2021 N Engl J Med 2021; 385:e100 https://doi.org/10.1056/NEJMe2119539.
Morens D, et al. "Universal Coronavirus Vaccines — An Urgent Need." NEJM December 15, 2021 https://doi.org/10.1056/NEJMp2118468.
Lilleri D, et al. "SARS-CoV-2 Infection in Vaccinated Health Care Workers." NEJM December 15, 2021 https://doi.org/10.1056/NEJMc2117119.
Chemaitelly H, et al. "Efficacy of Natural Immunity against SARS-CoV-2 Reinfection with the Beta Variant." NEJM December 15, 2021 https://doi.org/10.1056/NEJMc2110300.
Dunkle L, et al. "Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico." NEJM December 15, 2021 https://doi.org/10.1056/NEJMoa2116185.
Chemaitelly H, et al. "Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar." December 9, 2021 N Engl J Med 2021; 385:e83 https://doi.org/10.1056/NEJMoa2114114.
Levin E, et al. "Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months." December 9, 2021 N Engl J Med 2021; 385:e84 https://doi.org/10.1056/NEJMoa2114583.
Rubin E, et al. "Audio Interview: Waning Immunity against SARS-CoV-2." December 9, 2021 N Engl J Med 2021; 385:e99 https://doi.org/10.1056/NEJMe2119211.

Patel M, et al. "Booster Doses and Prioritizing Lives Saved." NEJM December 8, 2021 https://doi.org/10.1056/NEJMe2117592.
Bar-On Y, et al. "Protection against Covid-19 by BNT162b2 Booster across Age Groups." NEJM December 8, 2021 https://doi.org/10.1056/NEJMoa2115926.
Arbel R, et al. "BNT162b2 Vaccine Booster and Mortality Due to Covid-19." NEJM December 8, 2021 https://doi.org/10.1056/NEJMoa2115624.
McGarry B, et al. "Nursing Home Staff Vaccination and Covid-19 Outcomes." NEJM December 8, 2021 https://doi.org/10.1056/NEJMc2115674.
Alunno A, et al. "Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations." Ann Rheum Dis. 2021 Dec 7. https://doi.org/10.1136/annrheumdis-2021-221575.
Neoh ZCF, et al. "Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis." Blood Adv. 2022 Apr 12;6(7):2014-2034. https://doi.org/10.1182/bloodadvances.2021006333.
Witberg G, et al. "Myocarditis after Covid-19 Vaccination in a Large Health Care Organization." December 2, 2021 N Engl J Med 2021; 385:2132-2139 https://doi.org/10.1056/NEJMoa2110737.
Caforio A, et al. "Receipt of mRNA Vaccine against Covid-19 and Myocarditis." December 2, 2021 N Engl J Med 2021; 385:2189-2190 https://doi.org/10.1056/NEJMe2116493.
Cornelius V, et al. "Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial." Lancet. 2021 Dec 2. https://doi.org/10.1016/S0140-6736(21)02717-3.
Sheikh A, et al. "BNT162b2 and ChAdOx1 nCoV-19 Vaccine Effectiveness against Death from the Delta Variant." December 2, 2021 N Engl J Med 2021; 385:2195-2197 https://doi.org/10.1056/NEJMc2113864.
Fauver J, et al. "Viral Dynamics of SARS-CoV-2 Variants in Vaccinated and Unvaccinated Persons." NEJM December 1, 2021 https://doi.org/10.1056/NEJMc2102507.
Rosenberg E, et al. "Covid-19 Vaccine Effectiveness in New York State." NEJM December 1, 2021 https://doi.org/10.1056/NEJMoa2116063.
Rubin E, et al. "Covid-19 mRNA Vaccines — Six of One, Half a Dozen of the Other." NEJM December 1, 2021 https://doi.org/10.1056/NEJMe2117446.
Dickerman B, et al. "Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans." NEJM December 1, 2021 https://doi.org/10.1056/NEJMoa2115463.
Kohler S, et al. "Vaccine-Induced Thrombocytopenia with Severe Headache." November 25, 2021 N Engl J Med 2021; 385:2103-2105 https://doi.org/10.1056/NEJMc2112974.
Murphy W, et al. "A Possible Role for Anti-idiotype Antibodies in SARS-CoV-2 Infection and Vaccination." NEJM November 24, 2021 https://doi.org/10.1056/NEJMcibr2113694.
Ongarj J, et al. "Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population." Vaccines (Basel). 2021 Nov 23;9(12). https://doi.org/10.3390/vaccines9121375.
Cosgrove C, et al. "Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial." Lancet Respir Med. 2021 Nov 17. https://doi.org/10.1016/S2213-2600(21)00409-4.
Cappel-Porter H, et al. "Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial." Lancet. 2021 Nov 11. https://doi.org/10.1016/S0140-6736(21)02329-1.
Monto A, et al. "The Future of SARS-CoV-2 Vaccination — Lessons from Influenza." November 11, 2021 N Engl J Med 2021; 385:1825-1827 https://doi.org/10.1056/NEJMp2113403.
Serhani MA, et al. "Vaccine versus Variants (3Vs): Are the COVID-19 Vaccines Effective against the Variants? A Systematic Review." Vaccines (Basel). 2021 Nov 10;9(11). https://doi.org/10.3390/vaccines9111305.
Torgovnick J, et al. "Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant." NEJM November 10, 2021 https://doi.org/10.1056/NEJMc2113090.
Walter E, et al. "Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age." November 9, 2021 https://doi.org/10.1056/NEJMoa2116298.
Baden L, et al. "Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase." November 4, 2021 N Engl J Med 2021; 385:1774-1785 https://doi.org/10.1056/NEJMoa2113017.
McClymont E, et al. "Systematic review of the safety, immunogenicity, and effectiveness of COVID-19 vaccines in pregnant and lactating individuals and their infants." Int J Gynaecol Obstet. 2021 Nov 4. https://doi.org/10.1002/ijgo.14008.
Santacatterina M, et al. "Prevention of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines." November 4, 2021 N Engl J Med 2021; 385:1817-1821 https://doi.org/10.1056/NEJMc2113575.
Santin A, et al. "VITT after ChAdOx1 nCoV-19 Vaccination." NEJM November 3, 2021 https://doi.org/10.1056/NEJMc2111026.
Baden L, et al. "Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge." NEJM November 3, 2021 https://doi.org/10.1056/NEJMc2115597.
Tartour E, et al. "Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review." Clin Microbiol Infect. 2021 Oct 28. https://doi.org/10.1016/j.cmi.2021.09.036.
Noorchashm H, et al. "Equivalency of Protection From Natural Immunity in COVID-19 Recovered Versus Fully Vaccinated Persons: A Systematic Review and Pooled Analysis." Cureus. 2021 Oct 28;13(10):e19102. https://doi.org/10.7759/cureus.19102. eCollection 2021 Oct.
Dagan N, et al. "Adverse Effects after BNT162b2 Vaccine and SARS-CoV-2 Infection, According to Age and Sex." NEJM October 27, 2021 https://doi.org/10.1056/NEJMc2115045.
Rubin E, et al. "Audio Interview: A New Look at Covid-19 Vaccine Boosters." October 21, 2021 N Engl J Med 2021; 385:e72 https://doi.org/10.1056/NEJMe2116820.

Magnus M, et al. "Covid-19 Vaccination during Pregnancy and First-Trimester Miscarriage." NEJM October 20, 2021 https://doi.org/10.1056/NEJMc2114466.
Kulper-Schiek W, et al. "Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the Delta (B.1.617.2) variant: second interim results of a living systematic review and meta-analysis, 1 January to 25 August 2021." Euro Surveill. 2021 Oct;26(41). 14 Oct 2021 https://doi.org/10.2807/1560-7917.ES.2021.26.41.2100920.
Rubin E, et al. "Audio Interview: Are Covid-19 Vaccine Boosters Necessary?" October 7, 2021 N Engl J Med 2021; 385:e63 https://doi.org/10.1056/NEJMe2115835.
Sanders J, et al. "Prevention of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines." November 4, 2021 N Engl J Med 2021; 385:1817-1821 https://doi.org/10.1056/NEJMc2113575.
Tian YC, et al. "Immunogenicity Rates After SARS-CoV-2 Vaccination in People With End-stage Kidney Disease: A Systematic Review and Meta-analysis." JAMA Netw Open. 2021 Oct 1;4(10):e2131749. https://doi.org/10.1001/jamanetworkopen.2021.31749.
Falsey A, et al. "Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine." NEJM September 29, 2021 https://doi.org/10.1056/NEJMoa2105290.
Shen Q, et al. "Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review." Vaccines (Basel). 2021 Sep 29;9(10). https://doi.org/10.3390/vaccines9101102.
Weinreich D, et al. "REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19." NEJM September 29, 2021 https://doi.org/10.1056/NEJMoa2108163.
Sikron FH, et al. "Real-world safety data for the Pfizer BNT162b2 SARS-CoV-2 vaccine, historical cohort study." Clin Microbiol Infect. 2021 Sep 27. https://doi.org/10.1016/j.cmi.2021.09.018.
Sahly H, et al. "Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase." NEJM September 22, 2021 https://doi.org/10.1056/NEJMoa2113017.
Pilishvili T, et al. "Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel." NEJM September 22, 2021 https://doi.org/10.1056/NEJMoa2106599.
Gonzalez PA, et al. "Safety and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine in a Subgroup of Healthy Adults in Chile." Clin Infect Dis. 2021 Sep 19. https://doi.org/10.1093/cid/ciab823.
Yeung WWY, et al. "Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong." Ann Rheum Dis. 2021 Oct 22. https://doi.org/10.1136/annrheumdis-2021-221571.
Toscani I, et al. "COVID-19 Vaccines in Cancer Patients. Seropositivity and Safety." Systematic Review and Meta-Analysis. Vaccines (Basel). 2021 Sep 20;9(9). https://doi.org/10.3390/vaccines9091048.
Rubin E, et al. "Audio Interview: New Evidence on SARS-CoV-2 Vaccine Boosters." September 16, 2021 N Engl J Med 2021; 385:e48 https://doi.org/10.1056/NEJMe2115200.
Lee G, et al. "The Importance of Context in Covid-19 Vaccine Safety." September 16, 2021 N Engl J Med 2021; 385:1138-1140 https://doi.org/10.1056/NEJMe2112543.
Lin C, et al. "BNT162b2 Covid-19 Vaccine in Adolescents." NEJM September 15, 2021 https://doi.org/10.1056/NEJMc2113394.
Thomas S, et al. "Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months." NEJM September 15, 2021 https://doi.org/10.1056/NEJMoa2110345.
Falsey A, et al. "SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3." NEJM September 15, 2021 https://doi.org/10.1056/NEJMc2113468.
Salih F, et al. "Vaccine-Induced Thrombocytopenia with Severe Headache." NEJM September 15, 2021 https://doi.org/10.1056/NEJMc2112974.
Okhotin A, "Effectiveness of an Inactivated SARS-CoV-2 Vaccine." NEJM September 15, 2021 https://doi.org/10.1056/NEJMc2112423.
Normark J, et al. "Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination." September 9, 2021 N Engl J Med 2021; 385:1049-1051 https://doi.org/10.1056/NEJMc2110716.
Ellington S, et al. "On Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons." NEJM September 8, 2021 https://doi.org/10.1056/NEJMc2113516.
Zauche L, et al. "Receipt of mRNA Covid-19 Vaccines and Risk of Spontaneous Abortion." NEJM September 8, 2021 https://doi.org/10.1056/NEJMc2113891.
Thompson M, et al. "Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings." NEJM September 8, 2021 https://doi.org/10.1056/NEJMoa2110362.
Dean N, et al. "Covid-19 Vaccine Effectiveness and the Test-Negative Design." NEJM September 8, 2021 https://doi.org/10.1056/NEJMe2113151.

Shah A, et al. "Effect of Vaccination on Transmission of SARS-CoV-2." NEJM September 8, 2021 https://doi.org/10.1056/NEJMc2106757.
Hung IF, et al. "Safety and Efficacy of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Different Vaccines at Phase 3." Vaccines (Basel). 2021 Sep 4;9(9). https://doi.org/10.3390/vaccines9090989.
Keehner J, et al. "Resurgence of SARS-CoV-2 Infection in a Highly Vaccinated Health System Workforce." NEJM September 1, 2021 https://doi.org/10.1056/NEJMc2112981.
Deepak P, et al. "Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis." Autoimmun Rev. 2021 Aug 30:102927. https://doi.org/10.1016/j.autrev.2021.102927.

Uzun G, et al. "No Correlation between Anti-PF4 and Anti–SARS-CoV-2 Antibodies after ChAdOx1 nCoV-19 Vaccination." August 25, 2021 NEJM https://doi.org/10.1056/NEJMc2111305.
Lee G, et al. "The Importance of Context in Covid-19 Vaccine Safety." NEJM August 25, 2021 https://doi.org/10.1056/NEJMe2112543.
Mei XW, et al. "Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study." BMJ. 2021 Aug 26;374:n1931. https://doi.org/10.1136/bmj.n1931.

Barda N, et al. "Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting." NEJM August 25, 2021 https://doi.org/10.1056/NEJMoa2110475.
Chen Y, et al. "Nervous and Muscular Adverse Events after COVID-19 Vaccination: A Systematic Review and Meta-Analysis of Clinical Trials." Vaccines (Basel). 2021 Aug 23;9(8). https://doi.org/10.3390/vaccines9080939.
Harris R, et al. "Effect of Vaccination on Household Transmission of SARS-CoV-2 in England." August 19, 2021 N Engl J Med 2021; 385:759-760 https://doi.org/10.1056/NEJMc2107717.
Verma A, et al. "Myocarditis after Covid-19 mRNA Vaccination." NEJM August 18, 2021 https://doi.org/10.1056/NEJMc2109975.
Young B, et al. "Pan-Sarbecovirus Neutralizing Antibodies in BNT162b2-Immunized SARS-CoV-1 Survivors." NEJM August 18, 2021 https://doi.org/10.1056/NEJMoa2108453.
Lange B, et al. "Breakthrough Infections in BNT162b2-Vaccinated Health Care Workers." NEJM August 18, 2021 https://doi.org/10.1056/NEJMc2108076.
Sun J, et al. "Efficacy and Safety of Corticosteroid Use in Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis." Infect Dis Ther. 2021 Aug 13. https://doi.org/10.1007/s40121-021-00518-3.
Andrews N, et al. "Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant." August 12, 2021 N Engl J Med 2021; 385:585-594 https://doi.org/10.1056/NEJMoa2108891.
Berman G, et al. "Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents." NEJM August 11, 2021 https://doi.org/10.1056/NEJMoa2109522.
Stuart ASV, et al. "Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial." Lancet. 2021 Aug 6. https://doi.org/10.1016/S0140-6736(21)01694-9.
Pavord S, et al. "Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis." NEJM August 11, 2021 https://doi.org/10.1056/NEJMoa2109908.
Hall V, et al. "Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients." NEJM August 11, 2021 https://doi.org/10.1056/NEJMc2111462.
Williams W, et al. "Third Time’s a Charm — Covid-19 Vaccine Hope for Solid-Organ Transplant Recipients." NEJM August 11, 2021 https://doi.org/10.1056/NEJMe2112866.
Bergwerk M, et al. "Covid-19 Breakthrough Infections in Vaccinated Health Care Workers." NEJM July 28, 2021 https://doi.org/10.1056/NEJMoa2109072.
Chen X, et al. "Evaluation of the safety profile of COVID-19 vaccines: a rapid review." BMC Med. 2021 Jul 28;19(1):173. https://doi.org/10.1186/s12916-021-02059-5.
Evans S, et al. "Vaccine Effectiveness Studies in the Field." July 21, 2021 NEJM https://doi.org/10.1056/NEJMe2110605.
Bernal J, et al. "Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant." July 21, 2021 NEJM https://doi.org/10.1056/NEJMoa2108891.
Struyf F, et al. "ChAdOx1 nCoV-19 Vaccine Efficacy against the B.1.351 Variant." NEJM July 21, 2021 https://doi.org/10.1056/NEJMc2110093.
Yousaf A, et al. "Household Transmission of SARS-CoV-2 from Children and Adolescents." July 21, 2021 NEJM https://doi.org/10.1056/NEJMc2031915.
Vygen-Bonnet S, et al. "Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a living systematic review, 1 January to 14 May 2021." Euro Surveill. 2021 Jul;26(28). https://doi.org/10.2807/1560-7917.ES.2021.26.28.2100563.
Luo J, et al. "Safety and effectiveness of SARS-CoV-2 vaccines: A systematic review and meta-analysis." J Med Virol. 2021 Jul 15. https://doi.org/10.1002/jmv.27203.

Gebre M, et al. "Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination." NEJM July 14, 2021 https://doi.org/10.1056/NEJMc2108829.
Akova M, et al. "Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey." Lancet. 2021 Jul 17;398(10296):213-222. https://doi.org/10.1016/S0140-6736(21)01429-X. Epub 2021 Jul 8.
Krause P, et al. "SARS-CoV-2 Variants and Vaccines." July 8, 2021 N Engl J Med 2021; 385:179-186 https://doi.org/10.1056/NEJMsr2105280.
Rubin E, et al. "Audio Interview: How Well Are Covid-19 Vaccines Working?" July 8, 2021 N Engl J Med 2021; 385:e15 https://doi.org/10.1056/NEJMe2111369.
Quinn S, et al. "Addressing Vaccine Hesitancy in BIPOC Communities — Toward Trustworthiness, Partnership, and Reciprocity." July 8, 2021 N Engl J Med 2021; 385:97-100 https://doi.org/10.1056/NEJMp2103104.
Peterson M, et al. "Breakthrough SARS-CoV-2 Infections in Prison after Vaccination." July 7, 2021 NEJM https://doi.org/10.1056/NEJMc2108479.
Pinsky B, et al. "Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants." July 7, 2021 NEJM https://doi.org/10.1056/NEJMc2107799.
Jara A, et al. "Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile." July 7, 2021 NEJM https://doi.org/10.1056/NEJMoa2107715.
Fan VS, et al. "Age differences in the association of comorbid burden with adverse outcomes in SARS-CoV-2." BMC Geriatr. 2021 Jul 6;21(1):415. https://doi.org/10.1186/s12877-021-02340-5.
Selby R, et al. "Therapeutic Plasma Exchange in Vaccine-Induced Immune Thrombotic Thrombocytopenia." July 7, 2021 NEJM https://doi.org/10.1056/NEJMc2109465.
Baxter DN, et al. "Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine." N Engl J Med. 2021 Jun 30. https://doi.org/10.1056/NEJMoa2107659.
Li C, et al. "Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial." Lancet Infect Dis. 2021 Jun 28. https://doi.org/10.1016/S1473-3099(21)00319-4.
Shaker M, et al. "The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-analysis, GRADE Assessment, and International Consensus Approach." J Allergy Clin Immunol Pract. 2021 Jun 18. pii: S2213-2198(21)00671-1. https://doi.org/10.1016/j.jaip.2021.06.006.
Riley L, et al. "mRNA Covid-19 Vaccines in Pregnant Women." June 17, 2021 N Engl J Med 2021; 384:2342-2343 https://doi.org/10.1056/NEJMe2107070.
Lai K, et al. "Thrombotic Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination." JAMA June 16, 2021 https://doi.org/10.1056/NEJMc2107227.
Hacisuleyman E, et al. "Vaccine Breakthrough Infections with SARS-CoV-2 Variants." June 10, 2021 N Engl J Med 2021; 384:2212-2218 https://doi.org/10.1056/NEJMoa2105000.
Rubin E, et al. "Audio Interview: Treating Complications of Covid Vaccination." June 10, 2021 N Engl J Med 2021; 384:e107 https://doi.org/10.1056/NEJMe2109757.
O’Connell S, et al. "Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19." June 10, 2021 N Engl J Med 2021; 384:2259-2261 https://doi.org/10.1056/NEJMc2103916.
Heininger U, et al. "Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19." NEJM June 9, 2021 https://doi.org/10.1056/NEJMc2107809.
Bourguignon A, et al. "Adjunct Immune Globulin for Vaccine-Induced Thrombotic Thrombocytopenia." NEJM June 9, 2021 https://doi.org/10.1056/NEJMoa2107051.
Blumenthal K, et al. "Delayed Large Local Reactions to mRNA Covid-19 Vaccines in Blacks, Indigenous Persons, and People of Color." NEJM June 9, 2021 https://doi.org/10.1056/NEJMc2108620.
Becker S, et al. "Identifying and Tracking SARS-CoV-2 Variants — A Challenge and an Opportunity." NEJM June 9, 2021 https://doi.org/10.1056/NEJMp2103859.
Greinacher A, et al. "Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination." June 3, 2021 N Engl J Med 2021; 384:2092-2101 https://doi.org/10.1056/NEJMoa2104840.
Makhado Z, et al. "Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351) 3 Citing Articles." June 3, 2021 N Engl J Med 2021; 384:2161-2163 https://doi.org/10.1056/NEJMc2104192.
Nixon D, et al. "Vaccine Breakthrough Infections with SARS-CoV-2 Variants." NEJM June 2, 2021 https://doi.org/10.1056/NEJMc2107808.
Takuva S, et al. "Thromboembolic Events in the South African Ad26.COV2.S Vaccine Study." NEJM June 2, 2021 https://doi.org/10.1056/NEJMc2107920.
Luo W, et al. "Efficacy and Safety of COVID-19 Vaccines in Phase III Trials: A Meta-Analysis." Vaccines (Basel). 2021 Jun 1;9(6). https://doi.org/10.3390/vaccines9060582.

Chen Y, et al. "Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac." The Lancet Published:May 27, 2021 https://doi.org/10.1016/S1473-3099(21)00287-5.
Kitchin N, et al. "Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents." N Engl J Med. 2021 May 27. https://doi.org/10.1056/NEJMoa2107456.
Volpp K, et al. "Incentives for Immunity — Strategies for Increasing Covid-19 Vaccine Uptake." NEJM May 26, 2021 https://doi.org/10.1056/NEJMp2107719.
Xia S, et al. "Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial." JAMA. 2021 May 26. https://doi.org/10.1001/jama.2021.8565.
Bhikha S, et al. "Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant." May 20, 2021 N Engl J Med 2021; 384:1899-1909 https://doi.org/10.1056/NEJMoa2103055.
White E, et al. "Incident SARS-CoV-2 Infection among mRNA-Vaccinated and Unvaccinated Nursing Home Residents." NEJM May 19, 2021 https://doi.org/10.1056/NEJMc2104849.
Abdool Karim S, et al. "New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications." May 13, 2021 N Engl J Med 2021; 384:1866-1868 https://doi.org/10.1056/NEJMc2100362.
Shaw R, et al. "Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data." The Lancet Published May 12, 2021 https://doi.org/10.1016/S0140-6736(21)01115-6.
Leidner D, et al. "Covid-19 Vaccine Acceptance in California State Prisons." NEJM May 12, 2021 https://doi.org/10.1056/NEJMc2105282.
Keehner J, et al. "More on SARS-CoV-2 Infection after Vaccination in Health Care Workers." NEJM May 12, 2021 https://doi.org/ 10.1056/NEJMc2106004.
Ghorbani S, et al. "Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Vaccines (Basel)." 2021 May 6;9(5). https://doi.org/10.3390/vaccines9050467.
Chemaitelly H, et al. "Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants." NEJM May 5, 2021 https://doi.org/10.1056/NEJMc2104974.
Leentjens J, et al. "COVID-19-associated coagulopathy and antithrombotic agents—lessons after 1 year." The Lancet Hematology Published:April 27, 2021 https://doi.org/10.1016/S2352-3026(21)00105-8.
Vandebosch A, et al. "Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19." N Engl J Med. 2021 Apr 21. https://doi.org/10.1056/NEJMoa2101544.
Shimabukuro T, et al. "Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons." NEJM April 21, 2021 DOI: 10.1056/NEJMoa2104983.
Baeck M, et al. "Delayed Large Local Reactions to mRNA Vaccines." NEJM April 21, 2021 https://doi.org/10.1056/NEJMc2104751.
Hacisuleyman E, et al. "Vaccine Breakthrough Infections with SARS-CoV-2 Variants." NEJM April 21, 2021 https://doi.org/10.1056/NEJMoa2105000.
Cines D, et al. "SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia." NEJM April 16, 2021 https://doi.org/10.1056/NEJMe2106315.
Scully M, et al. "Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination." NEJM April 16, 2021 https://doi.org/10.1056/NEJMoa2105385.
Goel R, et al. "Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination." Science Immunology 15 Apr 2021: Vol. 6, Issue 58, eabi6950 https://doi.org/10.1126/sciimmunol.abi6950.
Kallam A, et al. "Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination." NEJM April 14, 2021 https://doi.org/10.1056/NEJMc2105869.
Yang F, et al. "Shared B cell memory to coronaviruses and other pathogens varies in human age groups and tissues." Science 12 Apr 2021: eabf6648 https://doi.org/10.1126/science.abf6648.
Greinacher A, et al. "Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination." NEJM April 9, 2021 https://doi.org/10.1056/NEJMoa2104840.
Mahase E, et al. "AstraZeneca vaccine: Blood clots are “extremely rare” and benefits outweigh risks, regulators conclude." BMJ 2021; 373 doi: https://doi.org/10.1136/bmj.n931 (Published 08 April 2021).
Krammer F, et al. "Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine." April 8, 2021 N Engl J Med 2021; 384:1372-1374 https://doi.org/10.1056/NEJMc2101667.
Katz I, et al. "From Vaccine Nationalism to Vaccine Equity — Finding a Path Forward." April 8, 2021 N Engl J Med 2021; 384:1281-1283 https://doi.org/10.1056/NEJMp2103614.
Lustig Y, et al. "Neutralizing Response against Variants after SARS-CoV-2 Infection and One Dose of BNT162b2." NEJM April 7, 2021 https://doi.org/10.1056/NEJMc2104036.
Makowski M, et al. "Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19." NEJM April 6, 2021 https://doi.org/10.1056/NEJMc2103916.
Coppola A, et al. "Factors Influencing the Efficacy of COVID-19 Vaccines: A Quantitative Synthesis of Phase III Trials." Vaccines (Basel). 2021 Apr 1;9(4). pii: vaccines9040341. https://doi.org/10.3390/vaccines9040341.
Quinn S, et al. "Addressing Vaccine Hesitancy in BIPOC Communities — Toward Trustworthiness, Partnership, and Reciprocity." NEJM March 31, 2021 https://doi.org/10.1056/NEJMp2103104.
Nachega J, et al. "Scaling Up Covid-19 Vaccination in Africa — Lessons from the HIV Pandemic." NEJM March 31, 2021 https://doi.org/10.1056/NEJMp2103313.
Keehner J, et al. "SARS-CoV-2 Infection after Vaccination in Health Care Workers in California." NEJM March 23, 2021 https://doi.org/10.1056/NEJMc2101927.
Nivet M, et al. "Early Evidence of the Effect of SARS-CoV-2 Vaccine at One Medical Center." NEJM March 23, 2021 https://doi.org/10.1056/NEJMc2102153.
Benenson S, et al. "BNT162b2 mRNA Covid-19 Vaccine Effectiveness among Health Care Workers." NEJM March 23, 2021 https://doi.org/10.1056/NEJMc2101951.

Bradley T, et al. "Antibody Responses after a Single Dose of SARS-CoV-2 mRNA Vaccine." NEJM March 23, 2021 https://doi.org/10.1056/NEJMc2102051.
Desmond A, et al. "On the Shoulders of Giants — From Jenner’s Cowpox to mRNA Covid Vaccines." NEJM March 20, 2021 https://doi.org/10.1056/NEJMp2034334.
Rubin E, et al. "Audio Interview: Efficacy of Current Covid-19 Vaccines against Variant Viruses." March 18, 2021 N Engl J Med 2021; 384:e53 https://doi.org/10.1056/NEJMe2104584.
Madhi S, et al. "Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant." NEJM March 16, 2021 https://doi.org/10.1056/NEJMoa2102214.
Altmann D, et al. "Immunity to SARS-CoV-2 variants of concern." Science 12 Mar 2021: Vol. 371, Issue 6534, pp. 1103-1104 https://doi.org/10.1126/science.abg7404.
Goralnick E, et al. "Mass-Vaccination Sites — An Essential Innovation to Curb the Covid-19 Pandemic." NEJM March 10, 2021 https://doi.org/10.1056/NEJMp2102535.
Estcourt L, et al. "Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial." medRxiv 2021.03.09.21252736; https://doi.org/10.1101/2021.03.09.21252736.
Liu Y, et al. "Neutralizing Activity of BNT162b2-Elicited Serum." NEJM March 8, 2021 https://doi.org/10.1056/NEJMc2102017.
Kadire S, et al. "Delayed Second Dose versus Standard Regimen for Covid-19 Vaccination." March 4, 2021 N Engl J Med 2021; 384:e28 https://doi.org/10.1056/NEJMclde2101987.
Blumenthal K, et al. "Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2." NEJM March 3, 2021 https://doi.org/10.1056/NEJMc2102131.
Kramer D, et al. "Choices in a Crisis — Individual Preferences among SARS-CoV-2 Vaccines." NEJM March 3, 2021 https://doi.org/10.1056/NEJMp2102146.
Blendon R, et al. "An Uncertain Public — Encouraging Acceptance of Covid-19 Vaccines." NEJM March 3, 2021 https://doi.org/10.1056/NEJMp2100351.
Walker S, et al. "SARS-CoV-2 Vaccines." JAMA. 2021;325(13):1318-1320. https://doi.org/10.1001/jama.2021.3199 February 26, 2021.
Lee T, et al. "Last-Mile Logistics of Covid Vaccination — The Role of Health Care Organizations." NEJM February 25, 2021 N Engl J Med 2021; 384:685-687 https://doi.org/10.1056/NEJMp2100574.
Rubin E, et al. "Audio Interview: The Real-World Effectiveness of Covid-19 Vaccination." February 25, 2021 N Engl J Med 2021; 384:e40 https://doi.org/10.1056/NEJMe2103272.
Dagan N, et al. "BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting." NEJM February 24, 2021 https://doi.org/10.1056/NEJMoa2101765.
Kreiss Y, et al. "Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients." The Lancet February 18, 2021 https://doi.org/10.1016/S0140-6736(21)00448-7.
Kojima N, et al. "The Covid-19 Vaccine-Development Multiverse." February 18, 2021 N Engl J Med 2021; 384:681-682. https://doi.org/10.1056/NEJMc2034838.
Klass P, et al. "Vaccinating Children against Covid-19 — The Lessons of Measles" February 18, 2021 N Engl J Med 2021; 384:589-591 https://doi.org/10.1056/NEJMp2034765.
Koch M, et al. "Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine — Preliminary Report." NEJM February 17, 2021 https://doi.org/10.1056/NEJMc2102179.
Rosenbaum L, et al. "Escaping Catch-22 — Overcoming Covid Vaccine Hesitancy." NEJM February 12, 2021 DOI: 10.1056/NEJMms2101220.
Ribas A, et al. "Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited." Cancer Discovery 11.2 (2021): 233-236. Web. 24 Mar. 2021. https://doi.org/10.1158/2159-8290.CD-20-1817 Published February 2021.
Shimabukuro T, et al. "Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US—December 14, 2020-January 18, 2021." JAMA. Published online February 12, 2021. https://doi.org/10.1001/jama.2021.1967.
Kachalia A, et al. "Who Goes First? Government Leaders and Prioritization of SARS-CoV-2 Vaccines." February 4, 2021 N Engl J Med 2021; 384:e15 https://doi.org/10.1056/NEJMpv2036128.
Schenkelberg T, et al. "Development and deployment of COVID-19 vaccines for those most vulnerable." Science Translational Medicine 03 Feb 2021: Vol. 13, Issue 579, eabd1525 https://doi.org/10.1126/scitranslmed.abd1525.
Shcheblyakov DV, et al. "Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia." Lancet. 2021 Feb 2. pii: S0140-6736(21)00234-8. https://doi.org/10.1016/S0140-6736(21)00234-8.
Beayni N, et al. "Available COVID-19 vaccine platforms: A roadmap to eclipsing the SARS-CoV-2 viral saga." Accepted 19-01-2021 The Internati onal Arabic Journal of Anti microbial Agents Vol. 11 No. 1:2 https://doi.org/10.3823/853.
“Placebo-Controlled Trials of Covid-19 Vaccines — Why We Still Need Them.” January 14, 2021 N Engl J Med 2021; 384:e2 https://doi.org/10.1056/NEJMp2033538.
Kimmel M., et al. “Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine.” JAMA January 13, 2021. https://doi.org/10.1056/NEJMoa2034201.
Doshi P, et al. "Peter Doshi: Pfizer and Moderna’s “95% effective vaccines—we need more details and the raw data" January 4, 2021.
Castells MC, et al. “Maintaining Safety with SARS-CoV-2 Vaccines.” N Engl J Med. 2020 Dec 30;NEJMra2035343. https://doi.org/10.1056/NEJMra2035343. Online ahead of print.
Essink B, et al. "Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine." N Engl J Med. 2020 Dec 30. https://doi.org/10.1056/NEJMoa2035389.
Anderson Evan, et al. "Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults." December 17, 2020. N Engl J Med 2020; 383:2427-2438. https://doi.org/10.1056/NEJMoa2028436.
D. F., et al. "Assessing Durability of Vaccine Effect Following Blinded Crossover in COVID-19 Vaccine Efficacy Trials." BMJ Yale December 14, 2020. https:doi.org/10.1101/2020.12.14.20248137.
Polack Fernando, et al. "Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine." NEJM December 10, 2020. https://doi.org/10.1056/NEJMoa2034577.
Madhi SA, et al. "Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK." Lancet. 2020 Dec 8. pii: S0140-6736(20)32661-1. https://doi.org/10.1016/S0140-6736(20)32661-1.
Haynes B, et al. "Prospects for a safe COVID-19 vaccine." Science Translational Medicine 04 Nov 2020: Vol. 12, Issue 568, eabe0948 https://doi.org/10.1126/scitranslmed.abe0948.
Cimolai N, et al. "Do RNA vaccines obviate the need for genotoxicity studies?" Mutagenesis, Volume 35, Issue 6, November 2020, Pages 509–510, https://doi.org/10.1093/mutage/geaa028.
Susanne H Hodgson, et al. “What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2.” Lancet Infect Dis . 2020 Oct 27; https://doi.org/10.1016/S1473-3099(20)30773-8.
Doshi P, et al. "Will covid-19 vaccines save lives? Current trials aren’t designed to tell us." BMJ 2020; 371 https://doi.org/10.1136/bmj.m4037 (Published 21 October 2020).
Ping Li, et al. "Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates." NEJM . October 14, 2020 https://doi.org/10.1056/NEJMoa2027906 .
Archana Koirala, et al. “Vaccines for COVID-19: The current state of play.” Paediatric Respiratory Reviews Volume 35, September 2020, Pages 43-49. https://doi.org/10.1016/j.prrv.2020.06.010.
Denis Y Logunov, et al. “Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2studies from Russia.” Lancet 2020, 396: 887-97. 26 September – 2 October 2020.
Keech Cheryl, et al. "Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine". NEJM September 2, 2020. https://doi.org/10.1056/NEJMoa2026920.
Jian-Ying Huang, et al. “Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.” The Lancet Volume 396, Issue 10249, 15–21 August 2020, Pages 479-488. https://doi.org/10.1016/S0140-6736(20)31605-6 .
Kizzmekia S. Corbett, et al. "Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates." NEJM July 28, 2020. https://doi.org/10.1056/NEJMoa2024671.
Zhu Feng-Cai, et al. “Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.” Lancet. 2020 Jun 13;395(10240):1845-1854. https://doi.org/10.1016/S0140-6736(20)31208-3. Epub 2020 May 22.

As part of K2P COVID-19 Series, K2P center is pleased to launch the latest product: “A Closer Look at COVID-19 Vaccines: The Known, the Unknown, and the Uncertain”. (Arabic Version) , (English Version) , (Full Product Version)

This is the second product on the COVID-19 Vaccine developed by K2P. To know more about the first product, you can check at: Countdown to a COVID-19 Vaccine: Spotlight on Lebanon

Images